CN120518738A - 具有心脏保护活性的蛋白质 - Google Patents

具有心脏保护活性的蛋白质

Info

Publication number
CN120518738A
CN120518738A CN202510498600.3A CN202510498600A CN120518738A CN 120518738 A CN120518738 A CN 120518738A CN 202510498600 A CN202510498600 A CN 202510498600A CN 120518738 A CN120518738 A CN 120518738A
Authority
CN
China
Prior art keywords
fam3b
vector
aav
chrdl1
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510498600.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·贾卡
G·罗齐
F·博尔托洛蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Centre for Genetic Engineering and Biotechnology
Original Assignee
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Centre for Genetic Engineering and Biotechnology filed Critical International Centre for Genetic Engineering and Biotechnology
Publication of CN120518738A publication Critical patent/CN120518738A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
CN202510498600.3A 2019-04-30 2020-04-30 具有心脏保护活性的蛋白质 Pending CN120518738A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1906052.4A GB201906052D0 (en) 2019-04-30 2019-04-30 Proteins with cardioprotective activity
GB1906052.4 2019-04-30
CN202080032910.1A CN113795504B (zh) 2019-04-30 2020-04-30 具有心脏保护活性的蛋白质
PCT/EP2020/062156 WO2020221906A1 (en) 2019-04-30 2020-04-30 Proteins with cardioprotective activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080032910.1A Division CN113795504B (zh) 2019-04-30 2020-04-30 具有心脏保护活性的蛋白质

Publications (1)

Publication Number Publication Date
CN120518738A true CN120518738A (zh) 2025-08-22

Family

ID=66589570

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510498600.3A Pending CN120518738A (zh) 2019-04-30 2020-04-30 具有心脏保护活性的蛋白质
CN202080032910.1A Active CN113795504B (zh) 2019-04-30 2020-04-30 具有心脏保护活性的蛋白质

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080032910.1A Active CN113795504B (zh) 2019-04-30 2020-04-30 具有心脏保护活性的蛋白质

Country Status (25)

Country Link
US (3) US12569574B2 (cg-RX-API-DMAC7.html)
EP (2) EP3962534B1 (cg-RX-API-DMAC7.html)
JP (2) JP7707075B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220027829A (cg-RX-API-DMAC7.html)
CN (2) CN120518738A (cg-RX-API-DMAC7.html)
AU (1) AU2020267029A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021021626A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137662A1 (cg-RX-API-DMAC7.html)
DK (1) DK3962534T3 (cg-RX-API-DMAC7.html)
ES (1) ES2975422T3 (cg-RX-API-DMAC7.html)
FI (1) FI3962534T3 (cg-RX-API-DMAC7.html)
GB (1) GB201906052D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20240441T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066324T2 (cg-RX-API-DMAC7.html)
IL (1) IL287525A (cg-RX-API-DMAC7.html)
LT (1) LT3962534T (cg-RX-API-DMAC7.html)
MX (2) MX2021013298A (cg-RX-API-DMAC7.html)
PL (1) PL3962534T3 (cg-RX-API-DMAC7.html)
PT (1) PT3962534T (cg-RX-API-DMAC7.html)
RS (1) RS65469B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111267WA (cg-RX-API-DMAC7.html)
SI (1) SI3962534T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400151T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020221906A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202107778B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
WO2025253097A1 (en) * 2024-06-03 2025-12-11 Forcefield Therapeutics Limited Proteins with cardiopreservation activity
GB202415505D0 (en) * 2024-10-21 2024-12-04 King S College London Lipid nanoparticles for cardiac protection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003265867A1 (en) * 2002-08-29 2004-10-18 Oxford Glycosciences (Uk) Ltd. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
US7312079B1 (en) * 2005-10-06 2007-12-25 Lexicon Pharmaceuticals, Inc. Variants of FAM3C
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
US20130136738A1 (en) * 2010-01-26 2013-05-30 Zhaodan Cao Methods of Treating Glucose Metabolism Disorders
EP2533796A4 (en) * 2010-02-12 2013-12-04 Ngm Biopharmaceuticals Inc METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
KR102248900B1 (ko) 2011-09-30 2021-05-07 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY
US20170209621A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Use of chordin-like 1 or collagen vi with mesenchymal stem cells
KR102022021B1 (ko) * 2018-01-10 2019-09-18 한국과학기술연구원 심혈관 질환의 진단을 위한 바이오마커 및 이의 용도
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Also Published As

Publication number Publication date
JP2025107171A (ja) 2025-07-17
LT3962534T (lt) 2024-05-27
CN113795504B (zh) 2025-05-06
EP3962534A1 (en) 2022-03-09
MX2021013298A (es) 2021-12-10
EP4389211A2 (en) 2024-06-26
US20250057982A1 (en) 2025-02-20
SG11202111267WA (en) 2021-11-29
WO2020221906A1 (en) 2020-11-05
JP2022530168A (ja) 2022-06-27
RS65469B1 (sr) 2024-05-31
DK3962534T3 (da) 2024-04-15
AU2020267029A1 (en) 2021-12-23
US20220193260A1 (en) 2022-06-23
ES2975422T3 (es) 2024-07-05
ZA202309540B (en) 2025-12-17
SI3962534T1 (sl) 2024-08-30
EP4389211A3 (en) 2024-08-28
FI3962534T3 (fi) 2024-04-17
US12121594B2 (en) 2024-10-22
PT3962534T (pt) 2024-04-03
US12569574B2 (en) 2026-03-10
JP7707075B2 (ja) 2025-07-14
EP3962534B1 (en) 2024-02-21
GB201906052D0 (en) 2019-06-12
HRP20240441T1 (hr) 2024-06-21
IL287525A (en) 2021-12-01
CN113795504A (zh) 2021-12-14
CA3137662A1 (en) 2020-11-05
US20220387625A1 (en) 2022-12-08
HUE066324T2 (hu) 2024-07-28
SMT202400151T1 (it) 2024-05-14
MX2026002607A (es) 2026-04-01
ZA202107778B (en) 2024-02-28
BR112021021626A2 (pt) 2021-12-21
KR20260099232A (ko) 2026-06-26
PL3962534T3 (pl) 2024-06-10
KR20220027829A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
EA038695B1 (ru) Способы и композиции для переноса генов по сосудистой сети
US20250057982A1 (en) Proteins with cardioprotective activity
US7655467B2 (en) Compositions and methods for systemic nucleic acid sequence delivery
KR20210130158A (ko) Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
US11891616B2 (en) Transgene cassettes designed to express a human MECP2 gene
AU2017286623A1 (en) Dual overlapping adeno-associated viral vector system for expressing ABC4A
US20180099029A9 (en) Serca2 therapeutic compositions and methods of use
KR20230112672A (ko) 신경변성 질환을 위한 유전자 요법
EP4410988A1 (en) An aav2-vector variant for targeted transfer of genes
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
HK40113022A (en) Proteins with cardioprotective activity
HK40060308A (en) Proteins with cardioprotective activity
HK40060308B (en) Proteins with cardioprotective activity
EP4337779A1 (en) Vector system
US20260022402A1 (en) Recombinant adeno-associated viral vector for gene delivery
WO2025253097A1 (en) Proteins with cardiopreservation activity
KR20250169529A (ko) 유전자 요법을 위한 Bcl2-관련 아타노진 3(BAG3)을 인코딩하는 핵산
EP1689230A2 (en) Compositions and methods for systemic nucleic acid sequence delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination